Clinical Trial Update: Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Entrectinib as a single-agent upfront therapy for children under 3 with NTRK1/2/3 or ROS1-fused CNS tumors is currently recruiting, s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Tumors
• High-grade Glioma

Drugs mentioned

• Entrectinib (entrectinib)

Snippet

Sponsor: St. Jude Children's Research Hospital | Conditions: High Grade Glioma, CNS Tumor | Phase 2 | Status: RECRUITING